 |
|
|
| |
SILEN-C2: sustained virological response (SVR) and safety of BI 201335 combined with peginterferon alfa 2a and ribavirin (PegIFN/RBV) in chronic HCV genotype-1 patients with nonresponse to PegIFN/RBV
|
| |
| |
Reported by Jules Levin
EASL 2011 Berlin Germany March 31-April 3
M.S. Sulkowski,1 M. Bourliere,2 J.-P. Bronowicki,3 A. Streinu-Cercel,4 L. Preotescu,4 T. Asselah,5 J.-M. Pawlotsky,6 S. Shafran,7 S. Pol,8 F.A. Caruntu,4 S. Mauss,9 D. Larrey,10 C. Hafner,11 Y. Datsenko,11 J.O. Stern,12 R. Kubiak,11 W. Bocher,11 G. Steinmann11 On behalf of the SILEN-C2 study group
1Johns Hopkins University, Baltimore, MD, USA; 2Hopital Saint Joseph, Marseille, France; 3Hopital de Brabois, Vandoeuvre Cedex, France; 4"Prof. Dr. Matei Bals" Institute of Infectious Diseases, Bucharest, Romania; 5Hopital Beaujon, Clichy Cedex, France; 6Hopital Henri Mondor, Creteil, France; 7University of Alberta, Edmonton, AB, Canada; 8Hopital Cochin, Paris, France; 9Center for HIV and Hepatogastroenterology, Düsseldorf, Germany; 10Hopital Saint-Eloi, Montpellier Cedex, France; 11Boehringer Ingelheim Pharma, Biberach, Germany; 12Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA
|
| |
|
|
|
|
|
